Recapitulation of HDV infection in a fully permissive hepatoma cell line allows efficient drug evaluation.
Antiviral Agents
/ pharmacology
Drug Evaluation, Preclinical
/ methods
Hep G2 Cells
Hepatitis B virus
/ metabolism
Hepatitis Delta Virus
/ drug effects
Hepatitis delta Antigens
/ metabolism
Humans
Immunity, Innate
/ drug effects
Inhibitory Concentration 50
Viral Envelope Proteins
/ metabolism
Virus Replication
/ drug effects
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
22 05 2019
22 05 2019
Historique:
received:
27
09
2018
accepted:
22
04
2019
entrez:
24
5
2019
pubmed:
24
5
2019
medline:
25
6
2019
Statut:
epublish
Résumé
Hepatitis delta virus (HDV) depends on the helper function of hepatitis B virus (HBV), which provides the envelope proteins for progeny virus secretion. Current infection-competent cell culture models do not support assembly and secretion of HDV. By stably transducing HepG2 cells with genes encoding the NTCP-receptor and the HBV envelope proteins we produce a cell line (HepNB2.7) that allows continuous secretion of infectious progeny HDV following primary infection. Evaluation of antiviral drugs shows that the entry inhibitor Myrcludex B (IC
Identifiants
pubmed: 31118422
doi: 10.1038/s41467-019-10211-2
pii: 10.1038/s41467-019-10211-2
pmc: PMC6531471
doi:
Substances chimiques
Antiviral Agents
0
Hepatitis delta Antigens
0
Viral Envelope Proteins
0
hepatitis delta virus large antigen
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2265Subventions
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : TRR179 (TP15/TP18)
Pays : International
Références
Gut. 2019 Jan;68(1):150-157
pubmed: 29217749
J Virol. 1989 May;63(5):1945-50
pubmed: 2649689
J Hepatol. 2014 Mar;60(3):538-44
pubmed: 24280293
J Hepatol. 2018 Jul;69(1):25-35
pubmed: 29524530
Gastroenterology. 2014 Jul;147(1):48-64
pubmed: 24768844
J Virol. 2004 Aug;78(15):8120-34
pubmed: 15254184
J Virol Methods. 2012 Jan;179(1):189-94
pubmed: 22108292
Science. 1992 May 29;256(5061):1331-3
pubmed: 1598578
J Hepatol. 2013 May;58(5):861-7
pubmed: 23246506
Antiviral Res. 2016 Dec;136:19-31
pubmed: 27771387
Viruses. 2017 Apr 10;9(4):
pubmed: 28394272
J Virol Methods. 2013 Oct;193(1):226-31
pubmed: 23764417
J Virol. 1993 Dec;67(12):7659-62
pubmed: 8230486
J Virol. 2004 Aug;78(15):7925-37
pubmed: 15254165
Antiviral Res. 2017 May;141:116-123
pubmed: 28223128
J Hepatol. 2015 Aug;63(2):346-53
pubmed: 25795587
J Hepatol. 2011 Jul;55(1):29-37
pubmed: 21145866
Elife. 2012 Nov 13;1:e00049
pubmed: 23150796
J Virol. 2003 May;77(9):5519-23
pubmed: 12692255
J Virol. 2018 May 14;92(11):
pubmed: 29437961
Hepatology. 2018 Apr;67(4):1224-1236
pubmed: 29152762
Lancet Infect Dis. 2015 Oct;15(10):1167-1174
pubmed: 26189433
Antimicrob Agents Chemother. 1997 Aug;41(8):1715-20
pubmed: 9257747
J Hepatol. 2016 Sep;65(3):490-8
pubmed: 27132170
Nat Methods. 2011 Jun 26;8(8):659-61
pubmed: 21706014
Gastroenterology. 2014 Apr;146(4):1070-83
pubmed: 24361467
Cell. 1994 Mar 11;76(5):853-64
pubmed: 8124721
J Virol. 2001 Jan;75(1):143-50
pubmed: 11119583
J Virol Methods. 2018 Oct;260:75-81
pubmed: 30031751
J Hepatol. 2016 Mar;64(3):556-64
pubmed: 26576481
Hepatology. 2015 Apr;61(4):1109-11
pubmed: 25348580
J Virol. 2013 Jul;87(14):7977-91
pubmed: 23678176
FEBS Lett. 2016 Jul;590(13):1915-26
pubmed: 27149321
Antiviral Res. 2015 Oct;122:112-29
pubmed: 26275800
Hepatology. 2016 Jan;63(1):35-48
pubmed: 26224662
Nat Rev Gastroenterol Hepatol. 2016 Oct;13(10):580-9
pubmed: 27534692
J Virol. 1994 Jun;68(6):4063-6
pubmed: 8189544